Once-daily Kaletra approved for some treatment-experienced adults

Michael Carter
Published: 29 April 2010

Drug regulatory authorities in the US have approved once-daily dosing of Kaletra for some treatment experienced-patients.

The Food and Drug Administration (FDA) announced on April 27th that once-daily dosing of Kaletra (lopinavir/ritonavir) was an option for treatment-experienced patients with fewer than three lopinavir-associated resistance mutations. Kaletra once daily is already an option for patients naive to antiretroviral therapy.

Approval for the once-daily dose (800mg lopinavir combined with 200mg ritonavir) was based upon the results of the M06-802 study. This showed that the once- and twice-daily treatment with the drug had comparable safety and efficacy.

A total of 599 treatment-experienced patients were enrolled in this study, and at baseline mean viral load was 4.3 log10 copies/ml.

Patients were randomised to receive either Kaletra once daily in combination with NRTIs, or twice-daily Kaletra (400 mg lopinavir combined with 100mg ritonavir), again in combination with NRTIs.

After 48 weeks, 57% of patients taking Kaletra once daily had a viral load below 50 copies/ml, compared with 54% of those taking twice-daily therapy.

Similar proportions of patients in the two arms of the study experienced virologic failure (22% vs 24%), and discontinued because of adverse events (13% vs 12%).

CD4 cell count increases were similar in the two study arms.

Diarrhoea, a common side-effect of protease inhibitors, was reported by 50% of those taking once-daily Kaletra compared to 39% of those taking the twice-daily dose.

Although similar proportions of patients taking once- and twice-daily doses of the drug achieved an undetectable viral load, the FDA has cautioned that patients with three or more lopinavir-associated resistance mutations should not be treated with the once-daily dose of the drug.

These resistance mutations are L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V.

Approval for once-daily use extends to both the tablet and liquid formulations of the drug.

However, the FDA stressed that Kaletra once daily is not recommended for paediatric use.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.